- Home
- SBFM vs SCNI Comparison
SBFM vs SCNI Comparison
Compare SBFM & SCNI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SBFM
- SCNI
- Stock Information
- Founded
- SBFM 2006
- SCNI 2003
- Country
- SBFM United States
- SCNI Israel
- Employees
- SBFM N/A
- SCNI N/A
- Industry
- SBFM Biotechnology: Pharmaceutical Preparations
- SCNI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SBFM Health Care
- SCNI Health Care
- Exchange
- SBFM Nasdaq
- SCNI Nasdaq
- Market Cap
- SBFM 3.7M
- SCNI 3.5M
- IPO Year
- SBFM N/A
- SCNI N/A
- Fundamental
- Price
- SBFM $3.00
- SCNI $3.65
- Analyst Decision
- SBFM
- SCNI
- Analyst Count
- SBFM 0
- SCNI 0
- Target Price
- SBFM N/A
- SCNI N/A
- AVG Volume (30 Days)
- SBFM 153.8K
- SCNI 31.9K
- Earning Date
- SBFM 11-11-2024
- SCNI 10-29-2024
- Dividend Yield
- SBFM N/A
- SCNI N/A
- EPS Growth
- SBFM N/A
- SCNI N/A
- EPS
- SBFM N/A
- SCNI N/A
- Revenue
- SBFM $30,481,982.00
- SCNI $284,000.00
- Revenue This Year
- SBFM $86.70
- SCNI N/A
- Revenue Next Year
- SBFM $126.76
- SCNI N/A
- P/E Ratio
- SBFM N/A
- SCNI N/A
- Revenue Growth
- SBFM 109.82
- SCNI N/A
- 52 Week Low
- SBFM $2.42
- SCNI $2.23
- 52 Week High
- SBFM $660.00
- SCNI $8.92
- Technical
- Relative Strength Index (RSI)
- SBFM 46.45
- SCNI 48.94
- Support Level
- SBFM $2.85
- SCNI $3.52
- Resistance Level
- SBFM $3.05
- SCNI $3.94
- Average True Range (ATR)
- SBFM 0.15
- SCNI 0.27
- MACD
- SBFM 0.02
- SCNI 0.00
- Stochastic Oscillator
- SBFM 43.59
- SCNI 52.31
About SBFM Sunshine Biopharma Inc.
Sunshine Biopharma Inc is a pharmaceutical company offering and researching life-saving medicines in a wide variety of therapeutic areas, including oncology and antivirals. The company is conducting a proprietary drug development program which is comprised of (i) K1.1 mRNA targeted for liver cancer, (ii) SBFM-PL4, PLpro protease inhibitor for SARS Coronavirus infections, and (iii) Adva-27a for pancreatic cancer. The company has two reportable segments: Prescription Generic Pharmaceuticals ("Generic Pharmaceuticals") and Nonprescription Over-The-Counter Products ("OTC Products"). The company generates the majority of its revenue from the Generic Pharmaceuticals segment.
About SCNI Scinai Immunotherapeutics Ltd.
Scinai Immunotherapeutics Ltd is a biopharmaceutical company focused on developing, manufacturing and commercializing products for the prevention and treatment of infectious diseases and other illnesses. It has executed eight clinical trials in seven countries, around 12,400 participants in the Phase 3 trial of its vaccine candidate and has built a GMP biologics manufacturing facility for biopharmaceutical products. The company is aiming to develop a pipeline of diversified and commercially viable products and platforms beginning with a nanosized antibody (NanoAb) pipeline.